N2-苯基-2,5-吡啶二胺 | 4928-44-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N2-苯基-2,5-吡啶二胺
• 英文名称: N²-phenylpyridine-2,5-diamine
• 英文别名: N²-phenyl-pyridine-2,5-diyldiamine；N²-Phenyl-pyridin-2,5-diyldiamin；2-N-phenylpyridine-2,5-diamine
• CAS: 4928-44-3
• 化学式: C₁₁H₁₁N₃
• mdl: MFCD07429598
• 分子量: 185.228
• InChiKey: NDNQUJQOJSNZGA-UHFFFAOYSA-N

物化性质

• 熔点：
  141 °C
• 沸点：
  379.8±22.0 °C(Predicted)
• 密度：
  1.226±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  N2-苯基-2,5-吡啶二胺 在 盐酸 、 sodium nitrite 、 sodium azide 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 2.5h， 生成 5-azido-N-phenylpyridin-2-amine
  参考文献：
  名称：

  Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi’s sarcoma-associated herpesvirus infections

  摘要：

  The Latency-associated nuclear antigen (LANA) plays a central role for the latent persistence of the Kaposi's Sarcoma Herpesvirus (KSHV) in the human host and helps to establish lifelong infections. Herein, we report our efforts towards hit-to-lead generation starting from a previously discovered LANADNA inhibitor. By tethering the viral genome to the host nucleosomes, LANA ensures the segregation and persistence of the viral DNA during mitosis. LANA is also required for the replication of the latent viral episome during the S phase of the cell cycle. We aim to inhibit the interaction between LANA and the viral genome to prevent the latent persistence of KSHV in the host organism. Medicinal chemistry-driven optimization studies and structure-activity-relationship investigation led to the discovery of an improved LANA inhibitor. The functional activity of our compounds was evaluated using a fluorescence polarization (FP)-based interaction inhibition assay and electrophoretic mobility shift assay (EMSA). Even though a crystal structure of the ligand protein complex was not available, we successfully conducted hit optimization toward a low micromolar protein-nucleic acid-interaction inhibitor. Additionally, we applied STD-NMR studies to corroborate target binding and to gain insights into the binding orientation of our most potent inhibitor, providing opportunities for further rational design of more efficient LANAtargeting anti KSHV agents in future studies. (C) 2020 The Author(s). Published by Elsevier Masson SAS.

  DOI：

  10.1016/j.ejmech.2020.112525
• 作为产物：
  描述：

  5-硝基-N-苯基吡啶-2-胺 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 0.33h， 生成 N2-苯基-2,5-吡啶二胺
  参考文献：
  名称：

  [EN] N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE N-(6-AMINOPYRIDIN-3-YL)-3-(SULFONAMIDO) BENZAMIDE COMME INHIBITEURS DE B-RAF POUR LE TRAITEMENT DU CANCER

  摘要：

  式(I)的化合物对于抑制Raf激酶是有用的。本文揭示了利用式(I)的化合物及其立体异构体和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病，或相关病理条件的方法。

  公开号：

  WO2009111280A1

文献信息

• [EN] N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS DE N-(6-AMINOPYRIDIN-3-YL)-3-(SULFONAMIDO) BENZAMIDE COMME INHIBITEURS DE B-RAF POUR LE TRAITEMENT DU CANCER
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009111280A1

  公开（公告）日：2009-09-11

  Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式(I)的化合物对于抑制Raf激酶是有用的。本文揭示了利用式(I)的化合物及其立体异构体和药学上可接受的盐，在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病，或相关病理条件的方法。
• Efficient and selective synthesis of alkoxy substituted di(pyridin-2-yl)amines and N-arylpyridin-2-ylamines
  作者：Irina-Claudia Grig-Alexa、Iuliana Simionescu、Oana-Irina Patriciu、Stéphane Massip、Adriana-Luminita Fînaru、Christian Jarry、Jean-Michel Léger、Gérald Guillaumet

  DOI：10.1016/j.tetlet.2012.01.084

  日期：2012.4

  The formation of alkoxy substituted di(pyridin-2-yl)amines and N-arylpyridin-2-ylamines by nitro group reduction is described. Unexpected substitution of ortho with the amino at C-6 was observed during the reduction using SnCl2·2H2O in different alcohols. The influence of the nature of the atom at the 3- and 5-positions of nitro-substituted di(pyridin-2-yl)amines and N-arylpyridin-2-ylamines was investigated

  描述了通过硝基还原形成烷氧基取代的二（吡啶-2-基）胺和N-芳基吡啶-2-基胺。在不同醇中使用SnCl 2 ·2H 2 O还原过程中，观察到C-6上氨基被邻位取代。研究了硝基取代的二（吡啶-2-基）胺和N-芳基吡啶-2-基胺的3-位和5-位原子性质的影响。
• Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
  申请人：Chao J. Hannguang

  公开号：US20050267119A1

  公开（公告）日：2005-12-01

  The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型吡啶基或苯基脲及其类似物，它们是人类P2Y1受体的选择性抑制剂。本发明还提供了各种相应的制药组合物和调节P2Y1受体活性的治疗疾病的方法。
• UREA ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS
  申请人：Chao Hannguang J.

  公开号：US20080280905A1

  公开（公告）日：2008-11-13

  The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y 1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y 1 receptor activity.

  本发明提供了新型吡啶基或苯基脲及其类似物，它们是选择性的人类P2Y1受体抑制剂。本发明还提供了各种该类药物组成物和调节P2Y1受体活性以治疗对其反应的疾病的方法。
• N- (6-AMINOPYRIDIN-3-YL) -3- (SULFONAMIDO) BENZAMIDE DERIVATIVES AS B-RAF INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Ahrendt Kateri A.

  公开号：US20110003859A1

  公开（公告）日：2011-01-06

  Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式(I)的化合物可用于抑制Raf激酶。本文揭示了使用式(I)的化合物及其立体异构体和药物可接受的盐，在哺乳动物细胞中进行体外、体内诊断、预防或治疗相关病理条件的方法。